|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stewart SL, Lakhani N, Brown PM, Larkin
OA, Moore AR and Hayes NS: Gynecologic cancer prevention and
control in the national comprehensive cancer control program:
Progress, current activities, and future directions. J Womens
Health (Larchmt). 22:651–657. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
La Vecchia C: Ovarian cancer: Epidemiology
and risk factors. Eur J Cancer Prev. 26:55–62. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Crosbie EJ, Kitson SJ, McAlpine JN,
Mukhopadhyay A, Powell ME and Singh N: Endometrial cancer. Lancet.
399:1412–1428. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hassani B, Attar Z and Firouzabadi N: The
renin-angiotensin- aldosterone system (RAAS) signaling pathways and
cancer: Foes versus allies. Cancer Cell Int. 23(254)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
George AJ, Thomas WG and Hannan RD: The
renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhao Y, Wang H, Li X, Cao M, Lu H, Meng Q,
Pang H, Li H, Nadolny C, Dong X and Cai L: Ang II-AT1R increases
cell migration through PI3K/AKT and NF-κB pathways in breast
cancer. J Cell Physiol. 229:1855–1862. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rasha F, Ramalingam L, Gollahon L, Rahman
RL, Rahman SM, Menikdiwela K and Moustaid-Moussa N: Mechanisms
linking the renin-angiotensin system, obesity, and breast cancer.
Endocr Relat Cancer. 26:R653–R672. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Coulson R, Liew SH, Connelly AA, Yee NS,
Deb S, Kumar B, Vargas AC, O'Toole SA, Parslow AC, Poh A, et al:
The angiotensin receptor blocker, Losartan, inhibits mammary tumor
development and progression to invasive carcinoma. Oncotarget.
8:18640–18656. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pei N, Mao Y, Wan P, Chen X, Li A, Chen H,
Li J, Wan R, Zhang Y, Du H, et al: Angiotensin II type 2 receptor
promotes apoptosis and inhibits angiogenesis in bladder cancer. J
Exp Clin Cancer Res. 36(77)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang
Y, Sun L, Sui G, Cai L and Dong X: Angiotensin II type 1 receptor
antagonists inhibit cell proliferation and angiogenesis in breast
cancer. Cancer Lett. 328:318–324. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Almutlaq M, Alamro AA, Alamri HS, Alghamdi
AA and Barhoumi T: The effect of local renin angiotensin system in
the common types of cancer. Front Endocrinol (Lausanne).
12(736361)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Okwan-Duodu D, Landry J, Shen XZ and Diaz
R: Angiotensin-converting enzyme and the tumor microenvironment:
Mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp
Physiol. 305:R205–R215. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fan F, Tian C, Tao L, Wu H, Liu Z, Shen C,
Jiang G and Lu Y: Candesartan attenuates angiogenesis in
hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Biomed Pharmacother. 83:704–711. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Nguyen NTH, Nguyen PA, Huang CW, Wang CH,
Lin MC, Hsu MH, Bao HB, Chien SC and Yang HC:
Renin-angiotensin-aldosterone system inhibitors and development of
gynecologic cancers: A 23 million individual population-based
study. Int J Mol Sci. 24(3814)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lee SH, Park J, Park RW, Shin SJ, Kim J,
Sung JD, Kim DJ and Yang K: Renin-angiotensin-aldosterone system
inhibitors and risk of cancer: A population-based cohort study
using a common data model. Diagnostics. 12(263)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang Z, Wei L, Yin C, Li W and Wan B:
Angiotensin receptor blocker associated with a decreased risk of
lung cancer: An updated meta-analysis. J Pers Med.
13(243)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Christian JB, Lapane KL, Hume AL, Eaton CB
and Weinstock MA: VATTC Trial. Association of ACE inhibitors and
angiotensin receptor blockers with keratinocyte cancer prevention
in the randomized VATTC trial. J Natl Cancer Inst. 100:1223–1232.
2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chiang YY, Chen KB, Tsai TH and Tsai WC:
Lowered cancer risk with ACE inhibitors/ARBs: A population-based
cohort study. J Clin Hypertens (Greenwich). 16:27–33.
2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yarmolinsky J, Díez-Obrero V, Richardson
TG, Pigeyre M, Sjaarda J, Paré G, Walker VM, Vincent EE, Tan VY,
Obón-Santacana M, et al: Genetically proxied therapeutic inhibition
of antihypertensive drug targets and risk of common cancers: A
mendelian randomization analysis. PLoS Med.
19(e1003897)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Copland E, Canoy D, Nazarzadeh M, Bidel Z,
Ramakrishnan R, Woodward M, Chalmers J, Teo KK, Pepine CJ, Davis
BR, et al: Antihypertensive treatment and risk of cancer: An
individual participant data meta-analysis. Lancet Oncol.
22:558–570. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang S, Xie L, Zhuang J, Qian Y, Zhang G,
Quan X, Li L, Yu H, Zhang W, Zhao W and Qian B: Association between
use of antihypertensive drugs and the risk of cancer: A
population-based cohort study in Shanghai. BMC Cancer.
23(425)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chen X, Yi CH and Ya KG: Renin-angiotensin
system inhibitor use and colorectal cancer risk and mortality: A
dose-response meta analysis. J Renin Angiotensin Aldosterone Syst.
21(1470320319895646)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sipahi I: Risk of cancer with
angiotensin-receptor blockers increases with increasing cumulative
exposure: Meta-regression analysis of randomized trials. PLoS One.
17(e0263461)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang
W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, et al:
Total neoadjuvant therapy with FOLFIRINOX in combination with
losartan followed by chemoradiotherapy for locally advanced
pancreatic cancer: A phase 2 clinical trial. JAMA Oncol.
5:1020–1027. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Uemura H, Hasumi H, Kawahara T, Sugiura S,
Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H and
Kubota Y: Pilot study of angiotensin II receptor blocker in
advanced hormone-refractory prostate cancer. Int J Clin Oncol.
10:405–410. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Passos-Silva DG, Verano-Braga T and Santos
RAS: Angiotensin-(1-7): Beyond the cardio-renal actions. Clin Sci
(Lond). 124:443–456. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Flores-Munoz M, Work LM, Douglas K, Denby
L, Dominiczak AF, Graham D and Nicklin SA: Angiotensin-(1-9)
attenuates cardiac fibrosis in the stroke-prone spontaneously
hypertensive rat via the angiotensin type 2 receptor. Hypertension.
59:300–307. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wichmann IA and Cuello MA: Obesity and
gynecological cancers: A toxic relationship. Int J Gynaecol Obstet.
155 (Suppl 1):S123–S134. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu Y, Yang J, Hilliard TS, Wang Z,
Johnson J, Wang W, Harper EI, Ott C, O'Brien C, Campbell L, et al:
Host obesity alters the ovarian tumor immune microenvironment and
impacts response to standard of care chemotherapy. J Exp Clin
Cancer Res. 42(165)2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cabandugama PK, Gardner MJ and Sowers JR:
The renin angiotensin aldosterone system in obesity and
hypertension: Roles in the cardiorenal metabolic syndrome. Med Clin
North Am. 101:129–137. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Thethi T, Kamiyama M and Kobori H: The
link between the renin-angiotensin-aldosterone system and renal
injury in obesity and the metabolic syndrome. Curr Hypertens Rep.
14:160–169. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Boustany CM, Bharadwaj K, Daugherty A,
Brown DR, Randall DC and Cassis LA: Activation of the systemic and
adipose renin-angiotensin system in rats with diet-induced obesity
and hypertension. Am J Physiol Regul Integr Comp Physiol.
287:R943–R949. 2004.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Schütten MTJ, Houben AJHM, De Leeuw PW and
Stehouwer CDA: The link between adipose tissue
renin-angiotensin-aldosterone system signaling and
obesity-associated hypertension. Physiology (Bethesda). 32:197–209.
2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yiannikouris F, Gupte M, Putnam K,
Thatcher S, Charnigo R, Rateri DL, Daugherty A and Cassis LA:
Adipocyte deficiency of angiotensinogen prevents obesity-induced
hypertension in male mice. Hypertension. 60:1524–1530.
2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yvan-Charvet L, Even P, Bloch-Faure M,
Guerre-Millo M, Moustaid-Moussa N, Ferre P and Quignard-Boulange A:
Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose
cell size and protects from diet-induced obesity and insulin
resistance. Diabetes. 54:991–999. 2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X
and He J: Hypertension and breast cancer risk: A systematic review
and meta-analysis. Sci Rep. 7(44877)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sun LM, Kuo HT, Jeng LB, Lin CL, Liang JA
and Kao CH: Hypertension and subsequent genitourinary and
gynecologic cancers risk: A population-based cohort study. Medicine
(Baltimore). 94(e753)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lindgren AM, Nissinen AM, Tuomilehto JO
and Pukkala E: Cancer pattern among hypertensive patients in North
Karelia, Finland. J Hum Hypertens. 19:373–379. 2005.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Cibula D, Raspollini MR, Planchamp F,
Centeno C, Chargari C, Felix A, Fischerová D, Jahnn-Kuch D, Joly F,
Kohler C, et al: ESGO/ESTRO/ESP guidelines for the management of
patients with cervical cancer-update 2023. Int J Gynecol Cancer.
33:649–666. 2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Oaknin A, Bosse TJ, Creutzberg CL,
Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza
MR, et al: Endometrial cancer: ESMO clinical practice guideline for
diagnosis, treatment and follow-up. Ann Oncol. 33:860–877.
2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Colombo N, Sessa C, Du Bois A, Ledermann
J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I,
Vergote I, et al: ESMO-ESGO consensus conference recommendations on
ovarian cancer: Pathology and molecular biology, early and advanced
stages, borderline tumours and recurrent disease. Ann Oncol.
30:672–705. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gil-Ibanez B, Davies-Oliveira J, Lopez G,
Díaz-Feijoo B, Tejerizo-Garcia A and Sehouli J: Impact of
gynecological cancers on health-related quality of life: Historical
context, measurement instruments, and current knowledge. Int J
Gynecol Cancer. 33:1800–1806. 2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Graham SV: The human papillomavirus
replication cycle, and its links to cancer progression: A
comprehensive review. Clin Sci (Lond). 131:2201–2221.
2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Balasubramaniam SD, Balakrishnan V, Oon CE
and Kaur G: Key molecular events in cervical cancer development.
Medicina (Kaunas). 55(384)2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kurnia I, Rauf S, Hatta M, Arifuddin S,
Hidayat YM, Natzir R, Kaelan C, Bukhari A, Pelupessy NU and
Patelonggi IJ: Molecular Patho-mechanisms of cervical cancer
(MMP1). Ann Med Surg (Lond). 77(103415)2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Park JS, Kim EJ, Kwon HJ, Hwang ES,
Namkoong SE and Um SJ: Inactivation of interferon regulatory
factor-1 tumor suppressor protein by HPV E7 oncoprotein.
Implication for the E7-mediated immune evasion mechanism in
cervical carcinogenesis. J Biol Chem. 275:6764–6769.
2000.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ashrafi GH, Haghshenas MR, Marchetti B,
O'Brien PM and Campo MS: E5 protein of human papillomavirus type 16
selectively downregulates surface HLA class I. Int J Cancer.
113:276–283. 2005.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Bhattacharjee R, Das SS, Biswal SS, Nath
A, Das D, Basu A, Malik S, Kumar L, Kar S, Singh SK, et al:
Mechanistic role of HPV-associated early proteins in cervical
cancer: Molecular pathways and targeted therapeutic strategies.
Crit Rev Oncol Hematol. 174(103675)2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Burd EM: Human papillomavirus and cervical
cancer. Clin Microbiol Rev. 16:1–17. 2003.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Pal A and Kundu R: Human papillomavirus E6
and E7: The cervical cancer hallmarks and targets for therapy.
Front Microbiol. 10(3116)2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Gius D, Funk MC, Chuang EY, Feng S,
Huettner PC, Nguyen L, Bradbury CM, Mishra M, Gao S, Buttin BM, et
al: Profiling microdissected epithelium and stroma to model genomic
signatures for cervical carcinogenesis accommodating for
covariates. Cancer Res. 67:7113–7123. 2007.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Vats A, Trejo-Cerro O, Thomas M and Banks
L: Human papillomavirus E6 and E7: What remains? Tumour Virus Res.
11(200213)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Lee JE, Chung Y, Rhee S and Kim TH: Untold
story of human cervical cancers: HPV-negative cervical cancer. BMB
Rep. 55:429–438. 2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Nicolás I, Marimon L, Barnadas E, Saco A,
Rodríguez-Carunchio L, Fusté P, Martí C, Rodriguez-Trujillo A,
Torne A, Del Pino M and Ordi J: HPV-negative tumors of the uterine
cervix. Mod Pathol. 32:1189–1196. 2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Zampronha Rde AC, Freitas-Junior R, Murta
EFC, Michelin MA, Barbaresco AA, Adad SJ, de Oliveira AM, Rassi AB
and Oton GJB: Human papillomavirus types 16 and 18 and the
prognosis of patients with stage I cervical cancer. Clinics (Sao
Paulo). 68:809–814. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Lu KH and Broaddus RR: Endometrial cancer.
N Engl J Med. 383:2053–2064. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Makker V, MacKay H, Ray-Coquard I, Levine
DA, Westin SN, Aoki D and Oaknin A: Endometrial cancer. Nat Rev Dis
Primers. 7(88)2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Crosbie EJ, Zwahlen M, Kitchener HC, Egger
M and Renehan AG: Body mass index, hormone replacement therapy, and
endometrial cancer risk: A meta-analysis. Cancer Epidemiol
Biomarkers Prev. 19:3119–3130. 2010.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Aune D, Navarro Rosenblatt DA, Chan DSM,
Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV and Norat
T: Anthropometric factors and endometrial cancer risk: A systematic
review and dose-response meta-analysis of prospective studies. Ann
Oncol. 26:1635–1648. 2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Renehan AG, Soerjomataram I, Tyson M,
Egger M, Zwahlen M, Coebergh JW and Buchan I: Incident cancer
burden attributable to excess body mass index in 30 European
countries. Int J Cancer. 126:692–702. 2010.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Yu K, Huang ZY, Xu XL, Li J, Fu XW and
Deng SL: Estrogen receptor function: Impact on the human
endometrium. Front Endocrinol (Lausanne). 13(827724)2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Joshi A and Ellenson LH: PI3K/PTEN/AKT
genetic mouse models of endometrial carcinoma. Adv Exp Med Biol.
943:261–273. 2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Terzic M, Aimagambetova G, Kunz J,
Bapayeva G, Aitbayeva B, Terzic S and Laganà AS: Molecular basis of
endometriosis and endometrial cancer: Current knowledge and future
perspectives. Int J Mol Sci. 22(9274)2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Ebring C, Marlin R, Macni J, Vallard A,
Bergerac S, Beaubrun-Renard M, Joachim C and Jean-Laurent M: Type
II endometrial cancer: Incidence, overall and disease-free survival
in Martinique. PLoS One. 18(e0278757)2023.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Ohgami T and Kato K: Pathogenesis of
endometrial cancer. In: Current Approaches to Endometrial Cancer.
Future Medicine Ltd, Unitec House, 2 Albert Place, London N3 1QB,
UK, pp18-32, 2014.
|
|
68
|
Miyamoto T and Shiozawa T: Two-sided role
of estrogen on endometrial carcinogenesis: stimulator or
suppressor? Gynecol Endocrinol. 35:370–375. 2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Lobo FD and Thomas E: Type II endometrial
cancers: A case series. J Midlife Health. 7:69–72. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Shen F, Gao Y, Ding J and Chen Q: Is the
positivity of estrogen receptor or progesterone receptor different
between type 1 and type 2 endometrial cancer? Oncotarget.
8:506–511. 2017.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Cancer Genome Atlas Research Network:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Testing strategies for Lynch syndrome in
people with endometrial cancer. Diagnostics guidance, 2020.
|
|
73
|
Stinton C, Jordan M, Fraser H, Auguste P,
Court R, Al-Khudairy L, Madan J, Grammatopoulos D and
Taylor-Phillips S: Testing strategies for Lynch syndrome in people
with endometrial cancer: Systematic reviews and economic
evaluation. Health Technol Assess. 25:1–216. 2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Liu Y, Patel L, Mills GB, Lu KH, Sood AK,
Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, et al:
Clinical significance of CTNNB1 mutation and Wnt pathway activation
in endometrioid endometrial carcinoma. J Natl Cancer Inst.
106(dju245)2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Kurnit KC, Kim GN, Fellman BM, Urbauer DL,
Mills GB, Zhang W and Broaddus RR: CTNNB1 (beta-catenin) mutation
identifies low grade, early stage endometrial cancer patients at
increased risk of recurrence. Mod Pathol. 30:1032–1041.
2017.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Prat J: Ovarian carcinomas: Five distinct
diseases with different origins, genetic alterations, and
clinicopathological features. Virchows Arch. 460:237–249.
2012.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Lheureux S, Gourley C, Vergote I and Oza
AM: Epithelial ovarian cancer. Lancet. 393:1240–1253.
2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Hollis RL: Molecular characteristics and
clinical behaviour of epithelial ovarian cancers. Cancer Lett.
555(216057)2023.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Irodi A, Rye T, Herbert K, Churchman M,
Bartos C, Mackean M, Nussey F, Herrington CS, Gourley C and Hollis
RL: Patterns of clinicopathological features and outcome in
epithelial ovarian cancer patients: 35 Years of prospectively
collected data. BJOG. 127:1409–1420. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Patch AM, Christie EL, Etemadmoghadam D,
Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey
PJ, et al: Whole-genome characterization of chemoresistant ovarian
cancer. Nature. 521:489–494. 2015.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Oza AM, Tinker AV, Oaknin A,
Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I,
Bell-McGuinn K, Coleman RL, O'Malley DM, et al: Antitumor activity
and safety of the PARP inhibitor rucaparib in patients with
high-grade ovarian carcinoma and a germline or somatic BRCA1 or
BRCA2 mutation: Integrated analysis of data from Study 10 and
ARIEL2. Gynecol Oncol. 147:267–275. 2017.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Boehm KM, Aherne EA, Ellenson L,
Nikolovski I, Alghamdi M, Vázquez-García I, Zamarin D, Long Roche
K, Liu Y, Patel D, et al: Multimodal data integration using machine
learning improves risk stratification of high-grade serous ovarian
cancer. Nat Cancer. 3:723–733. 2022.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Li W, Liu Y, Liu W, Tang ZR, Dong S, Li W,
Zhang K, Xu C, Hu Z, Wang H, et al: Machine learning-based
prediction of lymph node metastasis among osteosarcoma patients.
Front Oncol. 12(797103)2022.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Bahar ME, Kim HJ and Kim DR: Targeting the
RAS/RAF/MAPK pathway for cancer therapy: From mechanism to clinical
studies. Signal Transduct Target Ther. 8(455)2023.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Patel S, Rauf A, Khan H and Abu-Izneid T:
Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for
homeostasis and pathologies. Biomed Pharmacother. 94:317–325.
2017.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Martyniak A and Tomasik PJ: A new
perspective on the renin-angiotensin system. Diagnostics (Basel).
13(16)2022.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Mirabito Colafella KM, Bovée DM and Danser
AHJ: The renin-angiotensin-aldosterone system and its therapeutic
targets. Exp Eye Res. 186(107680)2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Fountain JH, Kaur J and Lappin SL:
Physiology, renin angiotensin system. In: StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing, 2024.
|
|
90
|
Sequeira-Lopez MLS and Gomez RA: Renin
cells, the kidney, and hypertension. Circ Res. 128:887–907.
2021.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Lu H, Cassis LA, Kooi CWV and Daugherty A:
Structure and functions of angiotensinogen. Hypertens Res.
39:492–500. 2016.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Mascolo A, Scavone C, Rafaniello C, De
Angelis A, Urbanek K, di Mauro G, Cappetta D, Berrino L, Rossi F
and Capuano A: The role of renin-angiotensin-aldosterone system in
the heart and lung: Focus on COVID-19. Front Pharmacol.
12(667254)2021.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Kawai T, Forrester SJ, O'Brien S, Baggett
A, Rizzo V and Eguchi S: AT1 receptor signaling pathways in the
cardiovascular system. Pharmacol Res. 125:4–13. 2017.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Maranduca MA, Clim A, Pinzariu AC,
Statescu C, Sascau RA, Tanase DM, Serban DN, Branisteanu DC,
Branisteanu DE, Huzum B and Serban IL: Role of arterial
hypertension and angiotensin II in chronic kidney disease (review).
Exp Ther Med. 25(153)2023.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Sun Y, Li Y, Wang M, Yue M, Bai L, Bian J,
Hao W, Sun J, Zhang S and Liu H: Increased AT2R
expression is induced by AT1R autoantibody via two axes,
Klf-5/IRF-1 and circErbB4/miR-29a-5p, to promote VSMC migration.
Cell Death Dis. 11(432)2020.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Fatima N, Patel SN and Hussain T:
Angiotensin II type 2 receptor: A target for protection against
hypertension, metabolic dysfunction, and organ remodeling.
Hypertension. 77:1845–1856. 2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Alenina N and dos Santos RAS:
Angiotensin-(1-7) and Mas. In: The Protective Arm of the Renin
Angiotensin System (RAS). Elsevier, pp155-159, 2015.
|
|
98
|
Pawlik MW, Kwiecien S, Ptak-Belowska A,
Pajdo R, Olszanecki R, Suski M, Madej J, Targosz A, Konturek SJ,
Korbut R and Brzozowski T: The renin-angiotensin system and its
vasoactive metabolite angiotensin-(1-7) in the mechanism of the
healing of preexisting gastric ulcers. The involvement of Mas
receptors, nitric oxide, prostaglandins and proinflammatory
cytokines. J Physiol Pharmacol. 67:75–91. 2016.PubMed/NCBI
|
|
99
|
Xu J, Fan J, Wu F, Huang Q, Guo M, Lv Z,
Han J, Duan L, Hu G, Chen L, et al: The ACE2/angiotensin-(1-7)/Mas
receptor axis: Pleiotropic roles in cancer. Front Physiol.
8(276)2017.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Luo Y, Tanabe E, Kitayoshi M, Nishiguchi
Y, Fujiwara R, Matsushima S, Sasaki T, Sasahira T, Chihara Y, Nakae
D, et al: Expression of MAS1 in breast cancer. Cancer Sci.
106:1240–1248. 2015.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Qaradakhi T, Apostolopoulos V and Zulli A:
Angiotensin (1-7) and alamandine: Similarities and differences.
Pharmacol Res. 111:820–826. 2016.PubMed/NCBI View Article : Google Scholar
|
|
102
|
da Silva FA, Rodrigues-Ribeiro L,
Melo-Braga MN, Passos-Silva DG, Sampaio WO, Gorshkov V, Kjeldsen F,
Verano-Braga T and Santos RAS: Phosphoproteomic studies of
alamandine signaling in CHO-MrgD and human pancreatic carcinoma
cells: An antiproliferative effect is unveiled. Proteomics.
22(e2100255)2022.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Patel VB, Zhong J-C, Grant MB and Oudit
GY: Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin
system in heart failure. Circ Res. 118:1313–1326. 2016.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Heyman SN, Walther T and Abassi Z:
Angiotensin-(1-7)-A potential remedy for AKI: Insights derived from
the COVID-19 pandemic. J Clin Med. 10(1200)2021.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Hrenak J, Paulis L and Simko F:
Angiotensin A/alamandine/MrgD axis: Another clue to understanding
cardiovascular pathophysiology. Int J Mol Sci.
17(1098)2016.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Philippe A: Unraveling the prevalence of
angiotensin II type 1 receptor antibodies in hypertension. Am J
Hypertens. 33:711–712. 2020.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Wagner MJ, Lyons YA, Siedel JH, Dood R,
Nagaraja AS, Haemmerle M, Mangala LS, Chanana P, Lazar AJ, Wang WL,
et al: Combined VEGFR and MAPK pathway inhibition in angiosarcoma.
Sci Rep. 11(9362)2021.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Catarata MJ, Ribeiro R, Oliveira MJ,
Robalo Cordeiro C and Medeiros R: Renin-angiotensin system in lung
tumor and microenvironment interactions. Cancers (Basel).
12(1457)2020.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Perea Paizal J, Au SH and Bakal C:
Squeezing through the microcirculation: Survival adaptations of
circulating tumour cells to seed metastasis. Br J Cancer.
124:58–65. 2021.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Saman H, Raza SS, Uddin S and Rasul K:
Inducing angiogenesis, a key step in cancer vascularization, and
treatment approaches. Cancers (Basel). 12(1172)2020.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Liu ZL, Chen HH, Zheng LL, Sun LP and Shi
L: Angiogenic signaling pathways and anti-angiogenic therapy for
cancer. Signal Transduct Target Ther. 8(198)2023.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Pinter M and Jain RK: Targeting the
renin-angiotensin system to improve cancer treatment: Implications
for immunotherapy. Sci Transl Med. 9(eaan5616)2017.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Brasier AR, Recinos A III and Eledrisi MS:
Vascular inflammation and the renin-angiotensin system.
Arterioscler Thromb Vasc Biol. 22:1257–1266. 2002.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Albulescu R, Codrici E, Popescu ID, Mihai
S, Necula LG, Petrescu D, Teodoru M and Tanase CP: Cytokine
patterns in brain tumour progression. Mediators Inflamm.
2013(979748)2013.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Liu B, Qu L and Yan S: Cyclooxygenase-2
promotes tumor growth and suppresses tumor immunity. Cancer Cell
Int. 15(106)2015.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Zhang RM, McNerney KP, Riek AE and
Bernal-Mizrachi C: Immunity and hypertension. Acta Physiol (Oxf).
231(e13487)2021.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Cao DY, Saito S, Veiras LC, Okwan-Duodu D,
Bernstein EA, Giani JF, Bernstein KE and Khan Z: Role of
angiotensin-converting enzyme in myeloid cell immune responses.
Cell Mol Biol Lett. 25(31)2020.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Perini MV, Dmello RS, Nero TL and Chand
AL: Evaluating the benefits of renin-angiotensin system inhibitors
as cancer treatments. Pharmacol Ther. 211(107527)2020.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Wang Q, Lei X, Zhu S and Zhang S:
Angiotensin-I converting enzyme inhibitors suppress angiogenesis
and growth of esophageal carcinoma xenografts. Dis Esophagus.
25:757–763. 2012.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Bryniarski P, Nazimek K and Marcinkiewicz
J: Immunomodulatory activity of the most commonly used
antihypertensive drugs-angiotensin converting enzyme inhibitors and
angiotensin II receptor blockers. Int J Mol Sci.
23(1772)2022.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Kunvariya AD, Dave SA, Modi ZJ, Patel PK
and Sagar SR: Exploration of multifaceted molecular mechanism of
angiotensin-converting enzyme 2 (ACE2) in pathogenesis of various
diseases. Heliyon. 9(e15644)2023.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Rosenthal T and Gavras I:
Renin-angiotensin inhibition in combating malignancy: A review.
Anticancer Res. 39:4597–4602. 2019.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Budiana ING, Angelina M and Pemayun TGA:
Ovarian cancer: Pathogenesis and current recommendations for
prophylactic surgery. J Turk Ger Gynecol Assoc. 20:47–54.
2019.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Martins FC, Couturier DL, Paterson A,
Karnezis AN, Chow C, Nazeran TM, Odunsi A, Gentry-Maharaj A, Vrvilo
A, Hein A, et al: Clinical and pathological associations of PTEN
expression in ovarian cancer: A multicentre study from the ovarian
tumour tissue analysis consortium. Br J Cancer. 123:793–802.
2020.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Huang L, Guo Z, Wang F and Fu L: KRAS
mutation: From undruggable to druggable in cancer. Signal Transduct
Target Ther. 6(386)2021.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Fujimoto Y, Morita TY, Ohashi A, Haeno H,
Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS and Mukohara T:
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor
overcomes resistance to anti-HER2 therapy in PIK3CA-mutant
HER2-positive breast cancer cells. Sci Rep.
10(21762)2020.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Harrington BS and Annunziata CM: NF-κB
signaling in ovarian cancer. Cancers (Basel).
11(1182)2019.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Zhang T, Ma C, Zhang Z, Zhang H and Hu H:
NF-κB signaling in inflammation and cancer. MedComm (2020).
2:618–653. 2021.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Regulska K, Michalak M, Kolenda T,
Kozłowska-Masłoń J, Guglas K and Stanisz B: Angiotensin-converting
enzyme inhibitors for ovarian cancer? -A new adjuvant option or a
silent trap. Rep Pract Oncol Radiother. 28:551–564. 2023.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Beyazit F, Ayhan S, Celik HT and Gungor T:
Assessment of serum angiotensin-converting enzyme in patients with
epithelial ovarian cancer. Arch Gynecol Obstet. 292:415–420.
2015.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Harding BN, Delaney JA, Urban RR and Weiss
NS: Post-diagnosis use of antihypertensive medications and the risk
of death from ovarian cancer. Gynecol Oncol. 154:426–431.
2019.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Piškur I, Topolovec Z, Bakula M, Zagorac
I, Milić Vranješ I and Vidosavljević D: Expression of vascular
endothelial growth factor-A (VEGF-A) in adenocarcinoma and squamous
cell cervical cancer and its impact on disease progression: Single
institution experience. Medicina (Lithuania).
59(1189)2023.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Zhou Y, Shu C and Huang Y: Fibronectin
promotes cervical cancer tumorigenesis through activating FAK
signaling pathway. J Cell Biochem. 120:10988–10997. 2019.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Zhou J, Yi Q and Tang L: The roles of
nuclear focal adhesion kinase (FAK) on cancer: A focused review. J
Exp Clin Cancer Res. 38(250)2019.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Mrozik KM, Blaschuk OW, Cheong CM,
Zannettino ACW and Vandyke K: N-cadherin in cancer metastasis, its
emerging role in haematological malignancies and potential as a
therapeutic target in cancer. BMC Cancer. 18(939)2018.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Spada S, Tocci A, Di Modugno F and Nisticò
P: Fibronectin as a multiregulatory molecule crucial in tumor
matrisome: From structural and functional features to clinical
practice in oncology. J Exp Clin Cancer Res. 40(102)2021.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Garvin AM, De Both MD, Talboom JS, Lindsey
ML, Huentelman MJ and Hale TM: Transient ACE
(angiotensin-converting enzyme) inhibition suppresses future
fibrogenic capacity and heterogeneity of cardiac fibroblast
subpopulations. Hypertension. 77:904–918. 2021.PubMed/NCBI View Article : Google Scholar
|
|
138
|
McLachlan CS: The angiotensin-converting
enzyme 2 (ACE2) receptor in the prevention and treatment of
COVID-19 are distinctly different paradigms. Clin Hypertens.
26(14)2020.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Wang R, Xu J, Wu J, Gao S and Wang Z:
Angiotensin-converting enzyme 2 alleviates pulmonary artery
hypertension through inhibition of focal adhesion kinase
expression. Exp Ther Med. 22(1165)2021.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Clarke NE, Fisher MJ, Porter KE, Lambert
DW and Turner AJ: Angiotensin converting enzyme (ACE) and ACE2 bind
integrins and ACE2 regulates integrin signalling. PLoS One.
7(e34747)2012.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Brooks SD, Smith RL, Moreira AS and
Ackerman HC: Oral lisinopril raises tissue levels of ACE2, the
SARS-CoV-2 receptor, in healthy male and female mice. Front
Pharmacol. 13(798349)2022.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Radin DP, Krebs A, Maqsudlu A and Patel P:
Our ACE in the HOLE: Justifying the use of angiotensin-converting
enzyme inhibitors as adjuvants to standard chemotherapy. Anticancer
Res. 38:45–49. 2018.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Stavropoulos A, Varras M, Vasilakaki T,
Varra VK, Tsavari A, Varra FN, Nonni A, Kavantzas N and Lazaris AC:
Expression of p53 and PTEN in human primary endometrial carcinomas:
Clinicopathological and immunohistochemical analysis and study of
their concomitant expression. Oncol Lett. 17:4575–4589.
2019.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Aslan O, Cremona M, Morgan C, Cheung LW,
Mills GB and Hennessy BT: Preclinical evaluation and reverse phase
protein Array-based profiling of PI3K and MEK inhibitors in
endometrial carcinoma in vitro. BMC Cancer. 18(168)2018.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Manning-Geist BL, Liu YL, Devereaux KA,
Paula ADC, Zhou QC, Ma W, Selenica P, Ceyhan-Birsoy O, Moukarzel
LA, Hoang T, et al: Microsatellite instability-high endometrial
cancers with MLH1 promoter hypermethylation have distinct molecular
and clinical profiles. Clin Cancer Res. 28:4302–4311.
2022.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Erickson BK, Najjar O, Damast S, Blakaj A,
Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M,
Cimino-Mathews A, et al: Human epidermal growth factor 2 (HER2) in
early stage uterine serous carcinoma: A multi-institutional cohort
study. Gynecol Oncol. 159:17–22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Elnashar AT, Hassab Elnaby NED, Abdellatef
AA and Salem MN: Her-2 neu expression in endometrial carcinoma. Med
J Cairo Univ. 86:69–76. 2018.
|
|
148
|
Florescu MM, Pirici D, Simionescu CE,
Stepan AE, Mărgăritescu C, Tudorache Ş and Ciurea RN: E-cadherin
and β-catenin immunoexpression in endometrioid endometrial
carcinoma. Rom J Morphol Embryol. 57:1235–1240. 2016.PubMed/NCBI
|
|
149
|
Delforce SJ, Lumbers ER, Corbisier de
Meaultsart C, Wang Y, Proietto A, Otton G, Scurry J, Verrills NM,
Scott RJ and Pringle KG: Expression of renin-angiotensin system
(RAS) components in endometrial cancer. Endocr Connect. 6:9–19.
2017.PubMed/NCBI View Article : Google Scholar
|
